Journal of
*Personalized Medicine*

IMPACT FACTOR 3.0
Indexed in: PubMed
CITESCORE 4.1

an Open Access Journal by MDPI

# Targeted Treatment of Lymphoma, Leukaemia and Myeloma

Guest Editor:

**Prof. Stephen Opat**
Department of Haematology, School of Clinical Sciences at Monash Health, Monash University, Wellington Rd, Clayton, VIC 3800, Australia

Deadline for manuscript submissions:
**closed (20 July 2021)**

## Message from the Guest Editor

Our understanding of tumor biology has led to the development of several therapies targeting specific genes and proteins involved in the growth and survival of cancer cells. This transformation is most apparent in lymphoma and leukaemia, where therapies targeting Bruton tyrosine kinase, phosphatidylinositol 3-kinase inhibitors, and B-cell lymphoma 2 are already in clinics.

The role of the immune system in tumor eradication has led to the development of second-generation CD20 antibodies, chimeric antigen receptor T-cells, and agents acting on key immune checkpoints. Agents acting on DNA methylation or histone protein modification are also active in certain lymphoid malignancies.

Several of these agents are superior to conventional chemoimmunotherapy although they are not without risks. This Special Issue will provide a comprehensive overview of current clinical research in lymphoma and leukaemia with special reference to targeted therapies, including the utility of specific drugs/combinations and strategies in various clinical and biological subgroups.

Journal of
*Personalized Medicine*

IMPACT FACTOR 3.0 | Indexed in: PubMed | CITESCORE 4.1

an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. David Alan Rizzieri**
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine* (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.
**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Journal of Personalized Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
𝕏@JPM_MDPI